Guardant Health ($GH) Insider Trading & Smart Money Activity
Guardant Health, Inc. ($GH) has 18 insider trades, 6 13F position changes and 8 analyst ratings on file. In the last 12 months on the open market, no insider bought and 3 insiders sold ($486.11K), net -$486.11K.
- Insider buyers (12 mo)
- 0
- Insider sellers (12 mo)
- 3
- Net insider $ (12 mo)
- -$486.11K
- Congress trades (12 mo)
- 0
- 13F moves on file
- 6
- Analyst ratings on file
- 8
GH insider buying and selling by quarter
| Quarter | Insider buys | Insider sales | Congress buys / sales | 13F added / cut |
|---|---|---|---|---|
| Q1 2026 | 0 | 0 | 0 / 0 | 0 / 0 |
| Q2 2026 | 0 | 3 · $475.08K | 0 / 0 | 1 / 5 |
| Q3 2026 | 0 | 0 | 0 / 0 | 0 / 0 |
| Q4 2026 | 0 | 1 · $11.03K | 0 / 0 | 0 / 0 |
Insider buys and sales count open-market trades only (Form 4 codes P and S). Grants, option exercises and tax withholding are left out.
All GH insider, congress, 13F and analyst activity
| Date | Source | Who | Action | Shares | Value / amount | ΔOwn | 1W | 1M | 6M | Filing | Story |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Insider | Azar Alex M IIDirector | Sell (Open-market sale) 10b5-1 | 69 sh | $11.03K | Read | ||||||
| Analyst | Morgan Stanley | Reiterates to Overweight | PT $200 | Read | |||||||
| Analyst | Barclays | Reiterates to Overweight | PT $220 | -3.2% | — | ||||||
| Analyst | Guggenheim | Reiterates to Buy | PT $200 | -5.3% | — | ||||||
| Analyst | BTIG | Reiterates to buy | PT $190 | -8.5% | -5.1% | Read | |||||
| Insider | Amirali TalasazCo-Chief Executive Officer | Sell (Option exercise) | 143.03K sh | +9.8% | -6.3% | Read | |||||
| Insider | Amirali TalasazCo-Chief Executive Officer | Buy (Option exercise) | 143.03K sh | $597.86K | +9.8% | -6.3% | Read | ||||
| Analyst | Guggenheim | Reiterates to buy | PT $160 | +9.8% | -6.3% | Read | |||||
| Insider | Amirali TalasazCo-Chief Executive Officer | Sell (Option exercise) | 111.80K sh | +13.1% | -2.5% | Read | |||||
| Insider | Amirali TalasazCo-Chief Executive Officer | Buy (Option exercise) | 111.80K sh | $467.34K | +13.1% | -2.5% | Read | ||||
| Analyst | Bernstein | Raises to buy | PT $175 | +13.1% | -2.5% | Read | |||||
| Analyst | Barclays | Reiterates to buy | PT $150 | +24.7% | +7.6% | Read | |||||
| Insider | Musa Tariq | Sell (Open-market sale) 10b5-1 | 1.95K sh | $255.89K | +19.3% | +17.0% | — | ||||
| Insider | Myrtle Potter | Sell (Open-market sale) 10b5-1 | 1.56K sh | $204.08K | +19.3% | +17.0% | — | ||||
| Insider | Roberto Mignone | Sell (Option exercise) | 264 sh | +19.3% | +18.2% | — | |||||
| Insider | Roberto Mignone | Buy (Option exercise) | 264 sh | +19.3% | +18.2% | — | |||||
| Insider | Musa Tariq | Sell (Open-market sale) 10b5-1 | 116 sh | $15.10K | +2.7% | +21.7% | — | ||||
| Insider | Musa Tariq | Sell (Option exercise) | 250 sh | -0.8% | +25.5% | — | |||||
| Insider | Musa Tariq | Buy (Option exercise) | 250 sh | -0.8% | +25.5% | — | |||||
| Insider | John SaiaChief Legal Officer | Sell (Option exercise) | 1.02K sh | -0.8% | +25.5% | — | |||||
| Insider | John SaiaChief Legal Officer | Buy (Option exercise) | 1.02K sh | -0.8% | +25.5% | — | |||||
| Insider | Chris FreemanChief Commercial Officer | Sell (Tax withholding) | 594 sh | $77.11K | -0.8% | +25.5% | — | ||||
| Insider | Chris FreemanChief Commercial Officer | Buy (Option exercise) | 1.40K sh | -0.8% | +25.5% | — | |||||
| Insider | Bell Michael BrianChief Financial Officer | Sell (Tax withholding) | 1.10K sh | $142.28K | -0.8% | +25.5% | — | ||||
| Insider | Bell Michael BrianChief Financial Officer | Buy (Option exercise) | 2.04K sh | -0.8% | +25.5% | — | |||||
| Analyst | RBC Capital | Reiterates to buy | PT $185 | -2.1% | +20.3% | Read | |||||
| 13F | Fred Alger Management | Added | +32.60K sh | $95.67M | +25.3% | +36.8% | — | ||||
| 13F | Driehaus Capital Management | Reduced | -618.91K sh | $234.34M | +25.3% | +36.8% | Read | ||||
| 13F | Lord, Abbett | Reduced | -89.87K sh | $291.97M | +19.6% | +31.6% | — | ||||
| 13F | Lord, Abbett | Reduced | -89.87K sh | $248.59M | +19.6% | +31.6% | — | ||||
| 13F | Baillie Gifford | Reduced | -1.03M sh | $593.29M | -0.8% | +30.5% | — | ||||
| 13F | Baillie Gifford | Reduced | -1.03M sh | $505.15M | -0.8% | +30.5% | — |
1W / 1M / 6M = how GH moved from the trade or filing date.
Insider trading in GH: who is buying and selling
| Insider | Role | Trades | Open-market net | Shares held | Last trade |
|---|---|---|---|---|---|
| Azar Alex M II | Director | 1 | -$11.03K | Oct 14, 2026 | |
| Amirali Talasaz | Co-Chief Executive Officer | 4 | — | Jun 29, 2026 | |
| Musa Tariq | 4 | -$271K | Jun 22, 2026 | ||
| Myrtle Potter | 1 | -$204.08K | Jun 22, 2026 | ||
| Roberto Mignone | 2 | — | Jun 21, 2026 | ||
| John Saia | Chief Legal Officer | 2 | — | Jun 15, 2026 | |
| Chris Freeman | Chief Commercial Officer | 2 | — | Jun 15, 2026 | |
| Bell Michael Brian | Chief Financial Officer | 2 | — | Jun 15, 2026 |
Institutions moving GH (13F)
Analyst ratings on GH
| Date | Firm | Action | Rating | Price target | 1W | 1M | 6M | Story |
|---|---|---|---|---|---|---|---|---|
| Morgan Stanley | Reiterates | Overweight | $185 → $200 | Read | ||||
| Barclays | Reiterates | Overweight | $200 → $220 | -3.2% | — | |||
| Guggenheim | Reiterates | Buy | $190 → $200 | -5.3% | — | |||
| BTIG | Reiterates | buy | $190 | -8.5% | -5.1% | Read | ||
| Guggenheim | Reiterates | buy | $160 | +9.8% | -6.3% | Read | ||
| Bernstein | Raises | buy | $175 | +13.1% | -2.5% | Read | ||
| Barclays | Reiterates | buy | $150 | +24.7% | +7.6% | Read | ||
| RBC Capital | Reiterates | buy | $185 | -2.1% | +20.3% | Read |
Frequently asked questions
Are GH insiders buying or selling?
Over the last 12 months 0 insiders made 0 open-market purchases worth $0 and 3 insiders made 4 open-market sales worth $486.11K, a net -$486.11K.
What is the latest insider trade in GH?
Azar Alex M II, Director filed a sell (open-market sale) of 69 sh worth $11.03K on Oct 14, 2026.
Which institutions changed their GH positions?
Recent 13F filers moving the stock include Lord, Abbett, Baillie Gifford, Fred Alger Management and Driehaus Capital Management.
Other diagnostics & research stocks
Data comes from public SEC Form 4 and 13F filings and STOCK Act disclosures. Dates are the trade or filing date reported. This page is for research only and is not investment advice.
Get a text when insiders, Congress or big funds trade a stock.
Free. Reply STOP anytime.